Magnetic fluid hyperthermia enhances cytotoxicity of bortezomib in sensitive and resistant cancer cell lines

International Journal of Nanomedicine

Volumn 9, Issue 1, 2013, Pages 145-153

  Alvarez Berríos, Merlis P ^a   Castillo, Amalchi ^a   Rinaldi, Carlos ^a,b   Torres Lugo, Madeline ^a  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^b University of Florida   (United States)

Author keywords

BZ; Enhanced cytotoxicity; Hot water hyperthermia; Magnetic fluid hyperthermia; Thermal sensitization

Indexed keywords

BORTEZOMIB; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BATH; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER RESISTANCE; CLINICAL EFFECTIVENESS; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; INTERMETHOD COMPARISON; MAGNETIC FLUID HYPERTHERMIA; NANOANALYSIS; NANOPHARMACEUTICS;

BZ; ENHANCED CYTOTOXICITY; HOT WATER HYPERTHERMIA; MAGNETIC FLUID HYPERTHERMIA; THERMAL SENSITIZATION;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CACO-2 CELLS; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; HYPERTHERMIA, INDUCED; MAGNETIC FIELD THERAPY; MAGNETIC FIELDS; MAGNETITE NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; PYRAZINES; TREATMENT OUTCOME;

EID: 84891505529     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S51435     Document Type: Article

References (39)

1. Wolf DH, Hilt W. The proteasome: a proteolytic nanomachine of cell regulation and waste disposal. Biochim Biophys Acta. 2004; 1695(1-3):19-31.
2. Miller J, Gordon C. The regulation of proteasome degradation by multi-ubiquitin chain binding proteins. FEBS Lett. 2005;579(15): 3224-3230.
3. Crews CM. Feeding the machine: mechanisms of proteasome-catalyzed degradation of ubiquitinated proteins. Curr Opin Chem Biol. 2003;7(5):534-539.
4. Kim HM, Yu Y, Cheng Y. Structure characterization of the 26S proteasome. Biochim Biophys Acta. 2011;1809(2):67-79.
5. Frankland-Searby S, Bhaumik SR. The 26S proteasome complex: an attractive target for cancer therapy. Biochim Biophys Acta. 2012;1825(1):64-76.
6. Wu WKK, Cho CH, Lee CW, et al. Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer Lett. 2010;293(1):15-22.
7. Farras R, Bossis G, Andermarcher E, Jariel-Encontre I, Piechaczyk M. Mechanisms of delivery of ubiquitylated proteins to the proteasome: new target for anti-cancer therapy? Crit Rev Oncol Hematol. 2005;54(1): 31-51.
8. Mateos MV, San Miguel JF. Bortezomib in multiple myeloma. Best Pract Res Clin Haematol. 2007;20(4):701-715.
9. Codony-Servat J, Tapia MA, Bosch M, et al. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther. 2006;5(3):665-675.
10. Mujtaba T, Dou QP. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med. 2011;12(67):471-480.
11. Xu H, Ju D, Jarois T, Xie Y. Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells. Breast Cancer Res Treat. 2008;107(2):267-274.
12. Ling X, Calinski D, Chanan-Khan AA, Zhou M, Li F. Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types. J Exp Clin Cancer Res. 2010;29:8.
13. Loeffler-Ragg J, Mueller D, Gamerith G, et al. Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib. Mol Cancer Ther. 2009;8(7):1995-2006.
14. de Wilt LH, Jansen G, Assaraf YG, et al. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. Biochem Pharmacol. 2012;83(2):207-217.
15. Smith AJ, Dai H, Correia C, et al. Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. J Biol Chem. 2011;286(20):17682-17692.
16. Shringarpure R, Catley L, Bhole D, et al. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol. 2006;134(2):145-156.
17. Vanakoski J, Seppala T. Heat exposure and drugs. A review of the effects of hyperthermia on pharmacokinetics. Clin Pharmacokinet. 1998;34(4):311-322.
18. Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget. 2011;2(3):209-221.
19. Milani V, Lorenz M, Weinkauf M, et al. Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells. Int J Hyperthermia. 2009;25(4):262-272.
20. Roti Roti JL. Cellular responses to hyperthermia (40-46 degrees C): cell killing and molecular events. Int J Hyperthermia. 2008;24(1):3-15.
21. Wust P, Hildebrandt B, Sreenivasa G, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002;3(8):487-497.
22. Habash RW, Bansal R, Krewski D, Alhafid HT. Thermal therapy, part 2: hyperthermia techniques. Crit Rev Biomed Eng. 2006;34(6):491-542.
23. Banerjee R, Katsenovich Y, Lagos L, McIintosh M, Zhang X, Li CZ. Nanomedicine: magnetic nanoparticles and their biomedical applications. Curr Med Chem. 2010;17(27):3120-3141.
24. Latorre M, Rinaldi C. Applications of magnetic nanoparticles in medicine: magnetic fluid hyperthermia. P R Health Sci J. 2009;28(3): 227-238.
25. Rodriguez-Luccioni HL, Latorre-Esteves M, Mendez-Vega J, et al. Enhanced reduction in cell viability by hyperthermia induced by magnetic nanoparticles. Int J Nanomedicine. 2011;6:373-380.
26. Lee JS, Rodriguez-Luccioni HL, Mendez J, et al. Hyperthermia induced by magnetic nanoparticles improves the effectiveness of the anticancer drug cis-diamminedichloroplatinum. J Nanosci Nanotechnol. 2011;11(5):4153-4157.
27. Alvarez-Berrios MP, Castillo A, Rinaldi C, Soto O, Rinaldi C, Torres-Lugo M. Hyperthermic potentiation of cisplatin by magnetic nanoparticle heaters is correlated with an increase in cell membrane fluidity. Int J Nanomedicine. 2013;8:1-11.
28. Herrera AP, Barrera C, Rinaldi C. Synthesis and functionalization of magnetite nanoparticles with aminopropylsilane and carboxymethyldextran. J Mater Chem. 2008;18(31):3650-3654.
29. Creixell M, Bohorquez AC, Torres-Lugo M, Rinaldi C. EGFR-targeted magnetic nanoparticle heaters kill cancer cells without a perceptible temperature rise. ACS Nano. 2011;5(9):7124-7129.
30. Pajonk F, van Ophoven A, McBride WH. Hyperthermia-induced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cells. Cancer Res. 2005;65(11):4836-4843.
31. Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys. 1984;10(6):787-800.
32. Bodell WJ, Cleaver JE, Roti Roti JL. Inhibition by hyperthermia of repair synthesis and chromatin reassembly of ultraviolet-induced damage to DNA. Radiat Res. 1984;100(1):87-95.
33. Cummings M. Increased c-fos expression associated with hyperthermia-induced apoptosis of a Burkitt lymphoma cell line. Int J Radiat Biol. 1995;68(6):687-692.
34. Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 2002;43(1):33-56.
35. Domenech M, Marrero-Berrios I, Torres-Lugo M, Rinaldi C. Lysosomal membrane permeabilization by targeted magnetic nanoparticles in alternating magnetic fields. ACS Nano. 7(6):5091-5101.
36. Oerlemans R, Franke NE, Assaraf YG, et al. Molecular basis of bortezomib resistance: proteasome subunit Î25 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008;112(6): 2489-2499.
37. Minderman H, Zhou Y, O'Loughlin K, Baer M. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemother Pharmacol. 2007;60(2):245-255.
38. Williamson MJ, Silva MD, Terkelsen J, et al. The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models. Mol Cancer Ther. 2009;8(12):3234-3243.
39. Zheng B, Zhou R, Gong Y, Yang X, Shan Q. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines. Int J Lab Hematol. 2012;34(3):237-247.